Eduardo Demondesert, MD
Gastroenterology · Fort Smith, ARNPI 1386675536
Payments from drug & device makers
Across 757 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Gilead$1K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$768
- Pfizer$756
- plus $3K from 26 others
What the payments were for
- Food & beverage$12,63798%
- Education$2722%
- Gifts$290%
- Entertainment$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 208 | $3,760 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 183 | $2,561 |
| Gilead | 75 | $1,245 |
| Johnson & Johnson | 57 | $1,180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $768 |
| Pfizer | 44 | $756 |
| Boston Scientific | 10 | $611 |
| Bristol Myers Squibb | 17 | $304 |
| Braintree Laboratories, Inc. | 31 | $232 |
| Nestle Healthcare Nutrition Inc. | 9 | $174 |
| Regeneron Healthcare Solutions, Inc. | 8 | $171 |
| Sanofi | 8 | $132 |
| Intercept Pharmaceuticals, Inc. | 7 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Ironwood Pharmaceuticals, Inc | 9 | $124 |
| Ipsen Biopharmaceuticals, Inc | 5 | $119 |
| QOL Medical, LLC | 5 | $93 |
| Merck | 5 | $80 |
| UCB, Inc. | 4 | $59 |
| Celltrion USA Inc. | 2 | $59 |
| Ardelyx, Inc. | 2 | $46 |
| Medtronic(2 entities) | 2 | $42 |
| Cook Medical LLC | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Redhill Biopharma Inc. | 2 | $28 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Mauna Kea Technologies, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
| Vivus LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,956 in reported general payments places this provider in the 70th percentile of 108 gastroenterology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 37 | $1,017,841 |
| Humira(Cf) PenAdalimumab | 62 | $584,292 |
| OcalivaObeticholic Acid | 24 | $263,307 |
| XifaxanRifaximin | 84 | $259,409 |
| CreonLipase/Protease/Amylase | 50 | $101,895 |
| XeljanzTofacitinib Citrate | 12 | $80,662 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 326 | $20,734 |
| LinzessLinaclotide | 32 | $20,112 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 102 | $16,617 |
| Mesalamine | 24 | $13,564 |
| MovantikNaloxegol Oxalate | 32 | $13,311 |
| Mesalamine ErMesalamine | 39 | $12,160 |
| VoqueznaVonoprazan Fumarate | 15 | $12,096 |
| Esomeprazole Magnesium | 216 | $9,177 |
| Budesonide DrBudesonide | 47 | $8,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,180 | $1,017,84137 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $2,561 | $264,657122 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $128 | $263,30724 claims |
| AbbVieCreon, Linzess | $3,760 | $122,00782 claims |
| PfizerXeljanz | $756 | $80,66212 claims |
| Braintree Laboratories, Inc.Sutab | $232 | $16,617102 claims |
| Redhill Biopharma Inc.Movantik | $28 | $13,31132 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $29 | $12,09615 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $13 | $8,52350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 108 gastroenterology providers in Arkansas.
Other gastroenterology in Fort Smith
- Hrair SimonianFort Smith$15K
- Christopher CrossFort Smith$12K
- Derrick RichardsonFort Smith$8K
- Whitfield KnappleNorth Little Rock$3.1M
- Glenn DavisLittle Rock$2.7M
- John BaberLittle Rock$1.8M
- Alonzo WilliamsLittle Rock$1.1M
- Johnathan GoodwinNorth Little Rock$570K
- Scott WoffordNorth Little Rock$535K
- Louis VelezLittle Rock$533K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.